ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO172

A Phase 2 Dose Ranging Study to Evaluate the Efficacy, Tolerability, and Safety of VS-505 in Hemodialysis Patients With Hyperphosphatemia

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Zhuang, Bing, Nanjing Medical University, Nanjing, Jiangsu, China
  • Liu, Bin, Wuxi People's Hospital, Wuxi, Jiangsu, China
  • Gan, Liangying, Peking University People's Hospital, Beijing, China
  • Yuan, Wei jie, Shanghai General Hospital, Shanghai, China
  • Shi, Ming, Wuhan University Renmin Hospital, Wuhan, Hubei, China
  • Peng, Ai, Shanghai Tenth People's Hospital, Shanghai, China
  • Wang, Lihua, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
  • Chen, Xiaolan, Affiliated Hospital of Nantong University, Nantong, China
  • Liu, Tongqiang, The Affiliated Changzhou No 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
  • Zhang, Shiying, Jilin Province People's Hospital, Changchun, Jilin, China
  • Liu, Hua Chang, Northern Jiangsu People's Hospital, Yangzhou City, Jiangsu Province, China
  • Gao, Qing, Zhongshan Hospital Xiamen University, Xiamen, China
  • Wang, Baoxing, Hebei Medical University Third Affiliated Hospital, Shijiazhuang, Hebei, China
  • Zheng, Hui Xiao, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, China
  • Wang, Song, Peking University Third Hospital, Beijing, China
  • Lin, Li Hong, First Affiliated Hospital of Dalian Medical University, Dalian, Dalian, China
  • He, Qiang, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
  • Zheng, Feng, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
  • Luo, Ping, Jilin University Second Hospital, Changchun, Jilin, China
  • Long, Gang, Tianjin People's Hospital, Tianjin, China
  • Lu, Wei, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China
  • Li, Kanghui, Guilin Medical University Affiliated Hospital, Guilin, Guizhou, China
  • Yang, Junwei, Nanjing Medical University, Nanjing, Jiangsu, China
  • Liu, Yingxue Cathy, Alebund Biotech Inc., Shanghai, China
  • Zuo, Li, Peking University People's Hospital, Beijing, China

VS-505 is a novel non-absorbed phosphate binder with the component of iron and gum Arabic. This was a phase II, 6-week open-label, randomized, active controlled dose-ranging study in hemodialysis (HD) patients with hyperphosphatemia. The primary objective was to investigate the ability of different fixed dose of VS-505 to lower serum phosphorus in this population.


Adult HD patients with serum phosphorus level between 6 - 10 mg/dL were randomized to VS-505 at dosages of 1.50, 2.25, 4.50, 6.75 g/d or sevelamer 4.80 g/d divided into 3 times administered orally with meals for 6 weeks. No dose titration was allowed. Patients were withdrawn if their serum phosphorus > 8.5mg/dL or < 2.5mg/dL during the treatment.


There were 133 patients randomized, 131 received the study drugs and 108 patients completed 6-week treatment. A statistically significant decrease in serum phosphorus level from baseline to end of treatment were observed in all VS-505 and sevelamer groups (Table 1). No significant changes of serum calcium, iPTH and iron parameters were observed during the treatment phase.
In pooled VS-505 groups, 81.0% patients reported ≥ 1 TEAE; discolored feces (51.4%) and diarrhea (10.5%) were most common TEAEs. No SAE was related to VS-505 as assessed by the investigator. 4.8% of VS-505 and 3.8% of sevelamer treated patients discontinued treatment due to AEs.


The dose-dependent serum phosphorus lowering effect of VS-505 has been demonstrated. VS-505 4.50 g/d, 6.75g/d and sevelamer 4.80 g/d groups showed clinically significant serum phosphorus reduction. VS-505 was safe and well tolerated in HD patients with hyperphosphatemia. Identifier: NCT04551300.

Table 1. Change in serum phosphorus from baseline to end of treament